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Abstract
Background: Ocular sebaceous carcinoma can masquerade as benign lesions resulting in delay of diagnosis. Early
recognition is even more difficult in young patients where the disease rarely occurs. Here, we provide a
clinicopathological correlation of ocular sebaceous carcinoma in a young individual lacking history of hereditary
cancer or immunosuppression.
Findings: A detailed histopathological study including p53 DNA sequencing was performed on an aggressive
sebaceous carcinoma presenting in a healthy 32 year-old Caucasian woman. She had no history of retinoblastoma,
evidence for a hereditary cancer syndrome, or radiation therapy. However, she potentially was at risk for excessive
UV light exposure. A detailed review of the literature is also provided.
A moderately well differentiated sebaceous carcinoma was established histopathologically arising from the
meibomian gland of the upper eyelid. In most areas, the cytoplasm contained small but distinct Oil-red-O positive
vacuoles. Direct sequencing of p53 identified a G:C®A:T mutation at a dipyrimidine site. The mutation results in
substitution of arginine for the highly conserved glycine at residue 199 located at the p53 dimer-dimer interface.
Energy minimization structural modeling predicts that G199R will neutralize negative charges contributed by
nearby inter- and intramonomeric glutamate residues.
Discussion: This study points to the importance of recognizing that sebaceous carcinoma can occur in young
patients with no evidence for hereditary cancer risk or radiation therapy. The G199R substitution is anticipated to
alter the stability of the p53 tetrameric complex. The role of UV light in the etiology of sebaceous carcinoma
deserves further study. Our findings, taken together with those of others, suggest that different environmental
factors could lead to the development of sebaceous carcinoma in different patients.
Background
Sebaceous carcinoma is generally considered to be a
tumor of older patients (mean age, 73 years of age) [1].
In the ocular adnexa, this highly malignant neoplasm
often masquerades as common benign lesions delaying
appropriate treatment [2-4]. For unknown reasons,
sebaceous carcinoma is more prevalent in the ocular
adnexa than elsewhere in the body. It can arise from the
meibomian glands, glands of Zeis, caruncle, skin of eye-
lid and eyebrow, lacrimal gland, or conjunctiva [4-8].
Although its etiology is largely unknown, it has been
associated with Asians [4,9], Muir-Torre syndrome
[10-14], Rb and p53 mutations [3,15,16], HIV [17], and
HPV [3,18]. The apparent increased rate of sebaceous
carcinoma in Asians/Pacific Islanders is being challenged
by recent studies indicating that the tumor is more
common in Whites [1,9], and showing a distribution
consistent with sunlight exposure [19].
Early recognition of sebaceous carcinoma is often
challenging, requiring close collaboration between
ophthalmologist and pathologist. Early stages of the dis-
ease can consist of only Pagetoid extension without
tumefaction [3]. This in situ stage can be mistaken for
blepharoconjunctivitis. Sebaceous carcinoma is often
clinically misdiagnosed as chalazion, a common lipogra-
nulomatous lesion of the eyelid. Furthermore, it is
important to recognize that Merkel and basal cell carci-
nomas can mimic sebaceous carcinoma microscopically.
Therefore, early diagnosis of sebaceous carcinoma
requires appreciation of its varied clinical presentation,
and recognition of entities that can mimic it histopatho-
logically [4].
Here we describe a sebaceous carcinoma presenting in
a 32 year-old woman. This case was previously included
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any medium, provided the original work is properly cited.in a series of seven cases [3]. Here, we revisit this case
to provide further clinical, histopathological and mole-
cular studies. The case emphasizes that this highly
aggressive cancer can occur in young patients without
history of retinoblastoma, radiation therapy, or heredi-
tary cancer syndrome. Finally, the case suggests that the
role of UV radiation and p53 mutations in sebaceous
carcinoma deserve further study.
Findings
Clinical history
A healthy 32 year-old Caucasian woman was referred
for a recurrent chalazion initially diagnosed 3 months
prior. She had no previous ocular or medical problems.
There was no significant family history of cancer (a
maternal uncle had hepatocellular carcinoma; her pater-
nal great grandmother reportedly had stomach cancer).
For 14 years she was a cosmetologist, and for 9 of those
years regularly used a home UV tanning bed.
Physical examination showed 2.0 mm of left eyelid
ptosis, and thickening of the tarsus and tarsal conjunc-
tiva (Figure 1A). Focal loss of eyelashes on the affected
eye was also appreciated (arrow in Figure 1B). The
remainder of her examination was unremarkable. She
had no bulbar injection or corneal findings. There was
no ocular discomfort, loss of vision, or motility deficit.
Biopsy of the left upper eyelid demonstrated sebaceous
carcinoma (see below). Resection with frozen section
control was performed. The resection included the
entire upper lid with the canalicular system. All eyelid
tissue from the medial to lateral canthal angle, and up
to the level of the superior fornix was excised. Four
months later, she presented with left eye proptosis and
pain. Her care was complicated by orbital extension
requiring exenteration of the left socket with neck dis-
section. The tumor had extensively infiltrated the orbital
fat, and extraocular muscles. The parotid gland and
three of seven anterior neck lymph nodes were also
involved. Despite this surgery, and adjuvant radiation
treatment, she died 2.5 years later of her disease.
Pathologic and molecular observations
The initial full thickness wedge biopsy revealed a moder-
ately well differentiated sebaceous carcinoma (grade II
[20]). Subsequently, the upper eyelid was removed under
frozen section control between the medial and lateral
canthal angles, and to the fornix superiorly. Histologi-
cally, the tumor filled the eyelid replacing most of the tar-
sus. The deep surgical margin was found to be focally
involved. The tumor had a lobular pattern and exten-
sively invaded the tarsus, dermis and muscle (Figure 2A).
There was no Pagetoid involvement of the conjunctiva or
epidermis. Mitotic figures were numerous, and often aty-
pical in appearance (Figure 2B, arrow). In most areas, the
cytoplasm contained small but distinct Oil-red-O positive
vacuoles. These vacuoles did not stain with mucicarmine
or periodic acid-Schiff (data not illustrated). The tumor
was previously shown to stain focally for epithelial mem-
brane antigen and p21
WAF1/CIP1; Bcl-2 was negative as
was HPV by in situ hybridization and PCR [3]; p53
showed striking nuclear positivity (see patient #6, table 1
of reference [3]) (Figure 3A).
To define the nature of the mutation responsible for
the p53 nuclear accumulation, we sequenced exons 5
through 9. To do this, DNA from a tumor metastasis was
extracted. Hematoxylin & eosin stained frozen sections
were used to establish that the portion of the tissue used
for the DNA extraction consisted only of tumor without
contaminating normal tissue. The DNA was extracted
and purified by acid-phenol chloroform [21]. From the
purified tumor genomic DNA, p53 exons 5 and 6, and 7
through 9 were amplified separately by PCR, and sub-
jected to automated fluorescence DNA sequencing using
magnetic beads, and dye-primer and dye-terminating che-
mistries. The strategy and primers used have been pre-
viously described [3]. DNA sequencing identified a G:
Figure 1 32 year-old cosmetologist presented with 3 month history of treatment for presumed chalazion. A) The left upper eyelid
showed 2 mm of ptosis with swelling. B) Focal loss of eye lashes was appreciated (arrow).
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Page 2 of 7C®A:T (GGA to AGA) missense mutation at a dipyrimi-
dine site in exon 6 (Figure 3B). The mutation results in
substitution of arginine for the highly conserved glycine
at codon 199 located at the dimer-dimer interface. Energy
minimization modeling shown in Figure 4 anticipates that
this substitution will significantly alter the ionic environ-
ment at the p53 dimer-dimer interface.
Discussion
Clinically, sebaceous carcinoma has a propensity to mas-
querade as a variety of common benign lesions. This has
contributed to an extended interval between presenta-
tion and appropriate treatment. In recent years, this gap
has been closing with improved awareness of its varied
clinical manifestations, and histopathological features.
The present case underlines that young age should not
exclude consideration of sebaceous carcinoma.
When ocular sebaceous carcinoma occurs at a young
age, it is generally associated with a predisposing factor
(Table 1). The youngest cases are from children with
bilateral retinoblastoma (8 and 12 years). Older patients
(17 and 28 years) had unilateral retinoblastoma.
Although radiation therapy may have played a role, it
may not be necessary as sebaceous carcinoma has
occurred outside the radiation field, and in a patient
who never received radiation or chemotherapy [22].
Muir-Torre syndrome, which is due to inactivation of
MSH2 or MLH1, predisposes to sebaceous tumors and
other neoplasms [23]. Genomic instability may provide a
mechanism for the occurrence of sebaceous carcinoma
in a 31 year-old man with Muir-Torre syndrome [24].
Early onset disease in the setting of HIV and steroid
treatment suggests a role for immunosuppression
[17,25]. In the present case, there was no history of reti-
noblastoma, radiation therapy or immunosuppression.
Furthermore, there was no clinical or family history sug-
gesting Muir-Torre syndrome, or another hereditary
cancer syndrome. Potential risk factors for this patient
were her 14-year employment as a cosmetologist, and
regular home-tanning bed use for 9 of those years.
Although this is speculative, a cancer risk has been asso-
ciated with hair dye exposure [26], and tanning bed use
[27].
Figure 2 Hematoxylin and eosin stained section from a full-thickness wedge resection. A) The tumor, which had no connection with the
conjunctival epithelium or epidermis, consisted of numerous lobules of invasive disease throughout the eyelid. C, conjunctiva; t, tarsus; m,
meibomian gland; asterisk, tumor lobules. B) High magnification shows a moderately differentiated sebaceous carcinoma with cytoplasmic lipid
vacuoles (arrowhead), and abnormal mitotic figures (arrow).
Figure 3 Analysis of p53 from the patient’s tumor. A) Elevated
nuclear p53 expression in tumor cells is shown in this paraffin
section by avidin-biotin complex immunohistochemistry. Control
sections, which received non-immune serum, showed no
immunoreactivity (data not illustrated). B) Automated fluorescent
DNA sequencing analysis (antisense strand) demonstrated a
missense mutation in exon 6 of p53. The upper and lower panels
show the wild-type and tumor sequences respectively. The
arrowhead shows the C®T mutation in the antisense strand.
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radiation in sebaceous carcinoma. A recent retrospective
study of 1,349 cases, showed that Caucasians are more
frequently affected with sebaceous carcinoma compared
to Asian/Pacific Islanders and Blacks [1]. Furthermore,
Rao et al. (1982) found only four Blacks among 75
patients with sebaceous carcinoma [28], and Zürcher et
al. (1998) noted no black patients in their series of 43
cases (42, Caucasian; one, Chinese) [8]. Finally, sebac-
eous carcinoma has occurred at nonocular sites in the
setting of radiation exposure [29,30] and sunlight [19].
Interestingly, the G199R substitution detected in our
patient was due to a G:C®A:T mutation at a
dipyrimidine site (GGA to AGA, sense strand; TCC to
TCT, antisense strand). UV light is known to cause
C®T substitutions at dipyrimidines, or CC®TT substi-
tutions in the p53 gene [31]. Although this class of
mutation is typical of UV light induced mutations, it
does not prove that the mutation was caused by UV
exposure. Among 11 cases of sebaceous carcinoma with
documented p53 mutations, 5 showed C®Tm u t a t i o n s
at dipyrimidine sites [15]. An additional reported case
from a 75 year-old woman showed a G:C®T:A typical
of bulky carcinogens [3]. The diversity of mutations sug-
gests that different mechanisms may play a role in dif-
ferent cases (Table 2).
Figure 4 Structural modeling shown here predicts that G199R will alter the ionic environment at the p53 dimer-dimer interface.T h e
X-ray coordinates for wild-type p53 were obtained from the RCSB PDB Protein Data Bank (ID 3KMD, deposited by Chen et al. (2010) [36]). The
structures were produced using the UCSF Chimera package. A) The ribbon representation shows the quaternary structure of the p53 tetramer
with bound DNA. The four p53 monomers are colored in gold (a), light blue (b), purple (c) and green (d). The DNA helix is in the center of the
tetramer. P53 monomers form inter-protein contacts across the DNA axis (dimers of monomer pairs d-c and a-b), and along the DNA axis
(between monomers d and a, between monomers c and b). The later are known as the “dimer-dimer” contacts. One of these interfaces is
represented by a sphere between monomers d and a. G199R is located at the center of this sphere. B) This panel shows an in silico energy
minimization performed within a 10Å sphere surrounding G199R. Molecular Operating Environment (MOE) was used for this analysis (release
2005.08, Chemical Computing Group, Montreal, Quebec). Energy-minimized monomers d and a are shown in magenta and cyan, respectively.
The modeling predicts that the substitution of arginine for glycine at position 199 will neutralize negative charges contributed by nearby inter-
and intramonomeric glutamate residues (E171 and E198, respectively).
Table 1 Risk factors of early onset (age < 40 years) ocular sebaceous carcinoma
Number of Patients Age Range in years Race
(Number of patients)
Risk factors References
11 8-30 C(4), U(7) Bilat-Rb; RT [16,20,40-46]
2 17, 28 U(2) Unilat-Rb; RT [47]
1 32 A(1) Unilat-Rb [48]
2 27, 37 U(2) RT [29,49]
1 31 U(1) Muir-Torre Syn. [12]
2 34, 36 U(2) HIV [17]
1 33 C(1) Steroid* [5]
1 20 A(1) None [50]
5 15-36 C(3), A(1), U(1) U [51,52]
1 32 C UV, Cosmetologist Present case
A, Asian; C, Caucasian; CT, chemotherapy; HIV, human immunodeficiency virus; Rb, retinoblastoma; RT, radiotherapy; U, unknown; *Steroid for idiopathic
thrombocytopenic purpura.
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G199R likely interferes with p53 function. Early X-ray
structures of p53 showed that the known “hot-spot”
mutations are often involved in DNA binding. However,
codon 199 lies outside of the direct DNA-protein bind-
ing site. Nevertheless, missense mutations of this codon
a r el i s t e di n4 8t u m o r si nt h eI n t e r n a t i o n a lA g e n c yf o r
Research on Cancer database [32]. Of those, 12 are
G199R substitutions [32]. In many of these cases, a link
between G199R and p53 function can be made. Cyclo-
phosphamide induced bladder cancer is more commonly
associated with G199R compared to sporadic, smoking-
related, and schistosomiasis-linked tumors [33]. In a
study of giant cell glioblastoma multiforme, G199R was
more often associated with evidence for microsatellite
instability compared to other mutations [34]. G199R,
which was observed in BRCA-1 associated familial
breast cancer [35], shows reduced activity in yeast trans-
activation capacity assays. Thus, although not directly
involved in DNA-protein binding, G199 appears to have
a critical role in p53 function.
X-ray crystallography is providing key insights into the
structure-function significance of p53 mutations [36].
An emerging picture is that p53 functions as homotetra-
meric complexes interacting with the DNA helix, and a
multitude of regulatory proteins. DNA-p53 and p53-p53
monomer contacts are important in stabilizing the tetra-
meric complex. The tetramer is composed of two p53
dimers each straddling the DNA helix. The dimers
come together through binding closely spaced DNA
decameric half-sites [37,38]. The resulting dimer-dimer
is further stabilized by specific p53-p53 interaction sites.
G199, which is located in such a key interface termed
“patch I”, makes critical contacts with residues of the
adjacent p53 monomer [39].
To evaluate the effect of the arginine substitution, in
silico energy minimization within a 10Å sphere sur-
rounding G199R was performed using the Molecular
Operating Environment (Figure 4B). Although the analy-
sis anticipates only a subtle conformational change in
the interface site, the electrostatic environment is signifi-
cantly altered. The arginine residue affects interactions
with other amino acids much more than the neutral gly-
cine residue originally did. The modeling predicts that
the substitution of arginine for glycine at position 199
will neutralize negative charges contributed by nearby
inter- and intramonomeric glutamate residues (E171
and E198, respectively). It is therefore likely that G199R
would destabilize the tetramer, acting in a dominant
negative manner reducing its DNA affinity, and disrupt-
ing cooperative interactions between its subunits, and
perhaps regulatory proteins. Taken together, the above
observations suggest that G199R probably contributed
to the molecular events leading to the development of
sebaceous carcinoma in this patient.
In summary, the present case emphasizes that young
age should not exclude consideration of sebaceous carci-
noma. Further studies are needed to determine if sebac-
eous carcinoma may arise through different sets of
environmental factors.
Consent
Next of kin could not be reached in order to gain con-
sent. There is no reason is suggest that consent would
not be given, and all efforts have been made to maintain
anonymity.
Table 2 Known p53 mutations in ocular sebaceous carcinoma
Age/Sex Site Mutation
Location Codon Amino acid Type
83 yrs/F [15] LL Exon 5 TACt to TAGt Y126stop C:G®G:C
75 yrs/M [15] ul Exon 5 GTG to ATG V173M G:C®A:T
36 yrs/F [15] LL Exon 5 CGC to CAC R175H G: C®A:T
78 yrs/M [15] ul Exon 6 CAT to CGT, AGT to GGT H193R, S215G A:T®G:C A:T®G:C
32 yrs/F* ul Exon 6 GGA to AGA G199R G:C®A:T
85 yrs/M [15] LL Exon 7 GGC to AGC G245S G:C®A:T
42 yrs/M [53] NP Exon 7 cCGG to cTGG R248Y C:G®T:A
76 yrs/F [15] LL Exon 7 cCGG to cTGG R248W C:G®T:A
61 yrs/M [15] LL Exon 8 gGTG to gATG V272M G:C®A:T
61 yrs/F [15] ul Exon 8 TGT to TAT C275Y G:C®A:T
75 yrs/F [3] LL Exon 8 TGT to TTT C277F G:C®T:A
47 yrs/F [15] ul Int 1 TGgt to TGtt NA G:C®T:A
68 yrs/M [15] LL Int 1 agGT to aaGT NA G:C®A:T
ul, Upper eyelid; LL, Lower eyelid; NA, Nonapplicable; NP, Not provided;
Underline, dipyrimidine; * present case
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